Genzyme's $150M plant upgrade starts to pay off

Sanofi ($SNY) says regulators have begun signing off on processes at its Genzyme plant in Waterford, Ireland, where it completed a $150 million upgrade earlier this year. The company says in a release that the FDA and the EMA have given approval to a filling and finishing operation for Myozyme and Lumizyme, treatments for the enzyme deficiency known as Pompe disease. This gives it nearly twice the capacity at the 4,000-liter bioreactor scale. It now will begin the process of getting approval to produce additional drugs at the facility. The facility, which employs about 500, also has lab facilities and administrative offices. Release | More

 

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.